TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04398017

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transesophageal echography
Description: Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transesophageal echography
Description: Ultrasound examination of the heart using a soft tube. The extremity is inserted through the mouth and positioned in the esophagus behind the heart.
Study: NCT03220009

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study: NCT03072017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT
Description: Breathing-based intervention
Study: NCT04346628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Favipiravir administered orally, 1800 mg on the first dose (day 1) followed by 800 mg twice daily for the next 9 days (days 2-10).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match favipiravir administered orally through day 10.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Description: Standard of care treatment for COVID-19 infection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care treatment
Description: Standard of care treatment for COVID-19 infection
Study: NCT03220009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo active surveillance

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study: NCT03503409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: 500 mg/day Oral of AG-120. AG-120 will be dispensed on Day 1 of each treatment cycle
Study: NCT04362735

Intervention type: DRUG
Intervention: Vedolizumab
Description: Vedolizumab 300 mg at weeks 0, 2 and 6 as induction. Maintenance every 4 or 8 weeks, as on-label recommendations.
Study: NCT01741129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP (SLE)
Description: PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal IMV (SLE)
Description: PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
Study: NCT03094663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with epinephrine
Description: bupivacaine 0.5% with epinephrine 30cc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Description: bupivacaine 0.5% with epinephrine 30cc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: 40 mg/ml, 1 ml
Study: NCT03188315

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: HPV oncogenes
Description: PCR and oncogenes detection

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: HPV oncogenes
Description: PCR and oncogenes detection
Study: NCT01447433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Energy restriction
Description: A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Energy restriction
Description: A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
Study: NCT02831452

Intervention type: OTHER
Intervention: pelvic floor muscle strength evaluation

Intervention type: OTHER
Intervention: pelvic floor muscle strength evaluation
Study: NCT03638947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Swab and decolonization using povidone-iodine cleansing
Description: Patient in this group will receive improved environmental cleaning and undergo surveillance using swabs and decolonization cleansing.
Study: NCT02836990

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena Incision Management System
Description: A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond
Description: A surgical skin adhesive used to prevent surgical wound infections
Study: NCT00891592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells
Description: Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.~Table 6: Dose escalation (Dose level CD3+ cell dose)~* 1xE5 cells/kg~* 2xE6 cells/kg~* 3xE7 cells/kg~* 4xE8 cells/kg
Study: NCT01213836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel XR- quetiapine fumarate extended release
Description: Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel XR- quetiapine fumarate extended release
Description: Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel IR - quetiapine fumarate
Description: Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel IR - quetiapine fumarate
Description: Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
Study: NCT00891592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation Arm
Description: Single infusion of Cord Blood Cells
Study: NCT03185871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
Study: NCT02653872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7986
Description: Oral solution, single dose, dilution from concentrate
Study: NCT01477190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Description: isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged \> 75 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Control Analgesia (PCA) Morphine
Description: PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
Study: NCT01327040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light exposure
Description: 12-hour light exposure of approximately 200 lux

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light exposure
Description: 12-hour light exposure of approximately 200 lux

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light exposure
Description: 12-hour light exposure of approximately 200 lux

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light exposure
Description: 12-hour light exposure of approximately 200 lux
Study: NCT01982604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-Inhalation Powder A
Description: Inhaled Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-Inhalation Powder A
Description: Inhaled Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-Inhalation Powder B
Description: Inhaled Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TI-Inhalation Powder B
Description: Inhaled Insulin
Study: NCT01850784

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High energy formula
Description: The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Description: The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
Study: NCT03738566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal self-dilation therapy
Description: Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.

Intervention type: DEVICE
Group type: OTHER
Intervention: Esophageal self-dilation therapy
Description: Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal self-dilation therapy
Description: Patient learns to pass a polyvinyl dilator orally on a routine basis. Teaching will take over 1-3 training sessions by one of two esophageal physicians and a nurse. Patients will be instructed to start Esophageal self dilation therapy twice a day for at least one week.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic therapy with esophageal dilation
Description: A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic therapy with esophageal dilation
Description: A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy with esophageal dilation
Description: A long, flexible tube is inserted down the throat into the esophagus and the narrow area of the esophagus is dilated, or stretched.
Study: NCT01213836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Seroquel XR
Description: Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Seroquel XR
Description: Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Seroquel IR
Description: Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Seroquel IR
Description: Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
Study: NCT05149924

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1012
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f ®
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
Study: NCT00670241

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol and betamethasone (LEO 80185 gel)
Description: Once daily application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 80185 vehicle
Description: Once daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacalcitol ointment
Description: Once daily application
Study: NCT02251977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM1
Description: GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
Study: NCT03094663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 40 mg/ml, 1 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 500 mg in 10 ml
Study: NCT02251977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 or XELOX
Description: mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient.
Study: NCT02653872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7986
Description: Oral solution, single dose, dilution from concentrate
Study: NCT03094663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: 500 mg in 10 ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8 MHz. Chiba needle
Description: 22G/ 4 inches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 MHz. Chiba needle
Description: 22G/ 4 inches

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine with Dexamethasone
Description: 15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 25cc
Description: 25 cc 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 25cc
Description: 25 cc 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 20cc
Description: 20cc 0.25% bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20cc
Description: 20cc 0.25% bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 2 mg IV dexamethasone.
Study: NCT04726501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with or without involved-field radiotherapy
Description: Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with or without involved-field radiotherapy
Description: Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined chemotherapy with or without involved-field radiotherapy
Description: Patients in low risk group receive 4 cycles of AVE-PC with or without involved-field radiotherapy (IFRT). Patients in intermediate risk group4 cycles ABVE-PC with or without IFRT. RERs in high risk group receive 4 cycles of ABVE-PC followed by followed by IFRT. SERs in high risk group receive 2 cycles of ABVE-PC followed by 2 cycles of IFOS/VINO and 2 cycles of ABVE-PC then followed by IFRT. IFRT consists of 21 Gy in 14 fractions of 1.5 Gy per day and is scheduled within 4 weeks after chemotherapy.
Study: NCT02251977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFOX6 or XELOX
Description: mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient.
Study: NCT02090764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozenoxacin
Study: NCT02653872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7986
Description: Oral solution, single dose, dilution from concentrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7986
Description: Oral solution, single dose, dilution from concentrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil
Description: Extended release tablet for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: Oral solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: Extended release capsule
Study: NCT01790880

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ORLA
Description: Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ORLA + Writing
Description: Treatment includes writing of sentences in combination with ORLA
Study: NCT00553943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 50 mg D3
Study: NCT02370563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FSPG
Description: 18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
Study: NCT02485236

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow oxygen via nasal cannula
Description: In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of \> 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Humidified Nasal High Flow Therapy
Description: Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen \> 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
Study: NCT00619645

Intervention type: DRUG
Group type: OTHER
Intervention: busulfan

Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine

Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate

Intervention type: DRUG
Group type: OTHER
Intervention: mycophenolate mofetil

Intervention type: PROCEDURE
Group type: OTHER
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: peripheral blood stem cell transplantation
Study: NCT02845856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: For each procedure, 10 billion cells will be infused in 4 times
Study: NCT04629118

Intervention type: DEVICE
Intervention: Selution SLR™ 018 Drug Eluting Balloon
Description: Target lesion will be pre-dilated with high pressure non-compliant balloon, then treated with SELUTION SLR™ 018 DEB Balloon.
Study: NCT00005840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo whole abdominal radiation therapy
Study: NCT01985906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple overlapping uncovered stents
Description: Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uncovered stents
Description: The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.